JP2024506029A - 四環系オキサゼピン化合物及びその使用 - Google Patents

四環系オキサゼピン化合物及びその使用 Download PDF

Info

Publication number
JP2024506029A
JP2024506029A JP2023547523A JP2023547523A JP2024506029A JP 2024506029 A JP2024506029 A JP 2024506029A JP 2023547523 A JP2023547523 A JP 2023547523A JP 2023547523 A JP2023547523 A JP 2023547523A JP 2024506029 A JP2024506029 A JP 2024506029A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
compound according
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506029A5 (https=
Inventor
スティーヴン ドー，
ルイス ジェー． ガザード，
サマンサ アリソン グリーン，
マシュー レオ ランドリー，
スシャント マルホトラ，
マイケル シウ，
リーミン チョン，
ユン－シン チョン，
ミンタオ ホー，
チエンフォン シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024506029A publication Critical patent/JP2024506029A/ja
Publication of JP2024506029A5 publication Critical patent/JP2024506029A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023547523A 2021-02-09 2022-02-07 四環系オキサゼピン化合物及びその使用 Pending JP2024506029A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/076369 2021-02-09
CN2021076369 2021-02-09
CN2022074435 2022-01-27
CNPCT/CN2022/074435 2022-01-27
PCT/US2022/015407 WO2022173678A1 (en) 2021-02-09 2022-02-07 Tetracyclic oxazepine compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2024506029A true JP2024506029A (ja) 2024-02-08
JP2024506029A5 JP2024506029A5 (https=) 2025-02-14

Family

ID=80445964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547523A Pending JP2024506029A (ja) 2021-02-09 2022-02-07 四環系オキサゼピン化合物及びその使用

Country Status (11)

Country Link
US (2) US20220281893A1 (https=)
EP (1) EP4291563A1 (https=)
JP (1) JP2024506029A (https=)
KR (1) KR20230145078A (https=)
CN (1) CN116867792A (https=)
AU (1) AU2022218927A1 (https=)
CA (1) CA3210167A1 (https=)
IL (1) IL304700A (https=)
MX (1) MX2023009135A (https=)
TW (1) TWI824405B (https=)
WO (1) WO2022173678A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023171353A1 (https=) * 2022-03-08 2023-09-14
JP2024510022A (ja) * 2021-03-17 2024-03-05 ▲勁▼方医▲薬▼科技（上海）有限公司 ピリミジン縮合環系化合物、その製造方法、及び使用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
EP4361157A4 (en) * 2021-06-21 2024-10-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
AU2022303440A1 (en) * 2021-07-02 2024-02-22 Shanghai De Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
US20250034166A1 (en) * 2021-09-27 2025-01-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4471037A1 (en) * 2022-01-30 2024-12-04 Shanghai Pharmaceuticals Holding Co., Ltd. Quinoline compound and use thereof
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CR20240508A (es) 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202408520A (zh) * 2022-07-08 2024-03-01 大陸商貝達藥業股份有限公司 Kras g12d抑制劑及其在醫藥上的應用
CN117430620A (zh) * 2022-07-22 2024-01-23 上海医药集团股份有限公司 嘧啶环类化合物、其中间体、其药物组合物及其应用
WO2024022444A1 (zh) 2022-07-27 2024-02-01 江苏恒瑞医药股份有限公司 稠环类化合物、其制备方法及其在医药上的应用
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
CN119923401A (zh) * 2022-09-23 2025-05-02 伊迪恩斯股份有限公司 新型四杂环化合物
TW202426459A (zh) * 2022-09-23 2024-07-01 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
AU2023388747A1 (en) * 2022-12-07 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused cyclic compounds and use thereof
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024153119A1 (en) * 2023-01-18 2024-07-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2024153180A1 (zh) * 2023-01-18 2024-07-25 上海艾力斯医药科技股份有限公司 杂环类化合物、其药物组合物及其用途
WO2024153116A1 (en) * 2023-01-18 2024-07-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
WO2024178304A1 (en) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Kras modulators
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024243186A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
TW202517649A (zh) * 2023-07-18 2025-05-01 大陸商泰勵生物科技（上海）有限公司 具有抗ｋｒａｓ突變腫瘤活性的化合物
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117430564A (zh) * 2023-10-18 2024-01-23 爱斯特（成都）生物制药股份有限公司 一种7-溴-2,6-二氯-5,8-二氟噻唑啉-4(3h)-酮的制备方法
WO2025111586A1 (en) * 2023-11-22 2025-05-30 Genentech, Inc. Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661556B (zh) * 2024-01-26 2025-12-09 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025209456A1 (zh) * 2024-04-03 2025-10-09 北京泰德制药股份有限公司 血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途
WO2025218798A1 (zh) * 2024-04-19 2025-10-23 领泰生物医药(绍兴)有限公司 Kras g12d降解剂及其制备方法和应用
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025256655A1 (zh) * 2024-06-14 2025-12-18 上海翰森生物医药科技有限公司 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026073024A1 (en) * 2024-09-30 2026-04-02 Gilead Sciences, Inc. Kras g12d inhibitors for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
PE20260440A1 (es) * 2018-11-09 2026-02-19 Hoffmann La Roche Compuestos de anillo fusionado
WO2021215544A1 (en) * 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CA3211725A1 (en) * 2021-03-17 2022-09-22 Tao Jiang Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
EP4361157A4 (en) * 2021-06-21 2024-10-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510022A (ja) * 2021-03-17 2024-03-05 ▲勁▼方医▲薬▼科技（上海）有限公司 ピリミジン縮合環系化合物、その製造方法、及び使用
JPWO2023171353A1 (https=) * 2022-03-08 2023-09-14

Also Published As

Publication number Publication date
CN116867792A (zh) 2023-10-10
US20250042919A1 (en) 2025-02-06
MX2023009135A (es) 2023-08-16
CA3210167A1 (en) 2022-08-18
IL304700A (en) 2023-09-01
US20220281893A1 (en) 2022-09-08
WO2022173678A1 (en) 2022-08-18
TW202241912A (zh) 2022-11-01
EP4291563A1 (en) 2023-12-20
AU2022218927A1 (en) 2023-08-03
AU2022218927A9 (en) 2024-09-19
KR20230145078A (ko) 2023-10-17
TWI824405B (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
TWI824405B (zh) 四環氧氮呯化合物及其用途
US12338256B2 (en) Aza-tetracyclic oxazepine compounds and uses thereof
JP7374960B2 (ja) 縮合環化合物
TWI868441B (zh) 非環氧氮呯化合物及其用途
TWI794533B (zh) 稠合環化合物
JP2025535367A (ja) ６－アザ部分を含むオキサゼピン化合物およびその使用
RU2783414C2 (ru) Соединения с конденсированными кольцами
RU2783706C1 (ru) Соединения с конденсированными кольцами
WO2025194134A1 (en) Linearly substituted oxazepin-5-one kras-g12d inhibitors
HK40098150A (zh) 四环氧氮杂䓬化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407